OPKO Health to Report Second Quarter 2022 Financial Results on August 4, 2022
July 25, 2022 16:05 ET
|
OPKO Health, Inc.
MIAMI, July 25, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2022 after the close of the U.S....
OPKO Health to Present at the 2022 Jefferies Healthcare Conference
June 02, 2022 08:00 ET
|
OPKO Health, Inc.
MIAMI, June 02, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in the 2022 Jefferies Healthcare Conference taking place June 8-10,...
OPKO Health Reports 2022 First Quarter Business Highlights and Financial Results
May 09, 2022 16:05 ET
|
OPKO Health, Inc.
MIAMI, May 09, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2022. Business Highlights ...
OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases
May 09, 2022 09:23 ET
|
OPKO Health, Inc.
Dr. Elias Zerhouni, ModeX Chairman, former President of Global R&D at Sanofi and former NIH Director, named President and Vice Chairman of OPKODr. Gary Nabel, ModeX President and CEO, former Chief...
OPKO Health to Report First Quarter 2022 Financial Results on May 9, 2022
May 05, 2022 16:05 ET
|
OPKO Health, Inc.
MIAMI, May 05, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2022 after the close of the U.S....
OPKO Health Reports 2021 Fourth Quarter Business Highlights and Financial Results
February 24, 2022 16:05 ET
|
OPKO Health, Inc.
MIAMI, Feb. 24, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended December 31, 2021. Business Highlights ...
OPKO Health to Report Fourth Quarter 2021 Financial Results on February 24, 2022
February 17, 2022 08:00 ET
|
OPKO Health, Inc.
MIAMI, Feb. 17, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended December 31, 2021 after the close of the U.S....
RAYALDEE® Launched in Germany by OPKO Health’s Licensee, VFMCRP
February 03, 2022 08:30 ET
|
OPKO Health, Inc.
MIAMI, Feb. 03, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces that Vifor Fresenius Medical Care Renal Pharma (VFMCRP) has initiated the commercial launch of RAYALDEE® (extended...
Japan’s MHLW Approves Pfizer and OPKO’s NGENLA® (Somatrogon), a New Long-Acting Treatment for Pediatric Growth Hormone Deficiency
January 20, 2022 08:00 ET
|
OPKO Health, Inc.; Pfizer Japan Inc.
TOKYO and MIAMI, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Pfizer Japan Inc. and OPKO Health, Inc. (NASDAQ: OPK) announced today that the next generation long-acting growth hormone injection, NGENLA®...
OPKO Health Announces Topline Results from Phase 2 Trial Evaluating RAYALDEE to Treat Symptomatic COVID-19 Outpatients
December 23, 2021 08:00 ET
|
OPKO Health, Inc.
MIAMI, Dec. 23, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces preliminary topline results from its Phase 2 trial with RAYALDEE® to treat mild-to-moderate COVID-19. This study...